{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:41:19Z","timestamp":1794440479425,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mega-projects of National Science Research for the 13th Five-Year Plan","award":["2017ZX10201101"],"award-info":[{"award-number":["2017ZX10201101"]}]},{"name":"Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences","award":["2018PT31042"],"award-info":[{"award-number":["2018PT31042"]}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation","doi-asserted-by":"crossref","award":["81871637"],"award-info":[{"award-number":["81871637"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The impacts of genetic polymorphisms on drug resistance mutations (DRMs) among various HIV-1 subtypes have long been debated. In this study, we aimed to analyze the natural polymorphisms and acquired DRM profile in HIV-1 CRF01_AE-infected patients in a large first-line antiretroviral therapy (ART) cohort in northeastern China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The natural polymorphisms of CRF01_AE were analyzed in 2034 patients from a long-term ART cohort in northeastern China. The polymorphisms in 105 treatment failure (TF) patients were compared with those in 1148 treatment success (TS) patients. The acquired DRM profile of 42 patients who experienced TF with tenofovir\/lamivudine\/efavirenz (TDF\/3TC\/EFV) treatment was analyzed by comparing the mutations at TF time point to those at baseline. The Stanford HIVdb algorithm was used to interpret the DRMs. Binomial distribution, McNemar test, Wilcoxon test and CorMut package were used to analyze the mutation rates and co-variation. Deep sequencing was used to analyze the evolutionary dynamics of co-variation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Before ART, there were significantly more natural polymorphisms of 31 sites on reverse transcriptase (RT) in CRF01_AE than subtype B HIV-1 (|Z value|\u2009\u2265\u20093), including five known drug resistance-associated sites (238, 118, 179, 103, and 40). However, only the polymorphism at site 75 was associated with TF (|Z value|\u2009\u2265\u20093). The mutation rate at 14 sites increased significantly at TF time point compared to baseline, with the most common DRMs comprising G190S\/C, K65R, K101E\/N\/Q, M184\u2009V\/I, and V179D\/I\/A\/T\/E, ranging from 66.7 to 45.2%. Moreover, two unknown mutations (V75\u2009L and L228R) increased by 19.0 and 11.9% respectively, and they were under positive selection (Ka\/Ks\u2009&gt;\u20091, log odds ratio [LOD]\u2009&gt;\u20092) and were associated with several other DRMs (cKa\/Ks\u2009&gt;\u20091, LOD\u2009&gt;\u20092). Deep sequencing of longitudinal plasma samples showed that L228R occurred simultaneously or followed the appearance of Y181C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The high levels of natural polymorphisms in CRF01_AE had little impact on treatment outcomes. The findings regarding potential new CRF01_AE-specific minor DRMs indicate the need for more studies on the drug resistance phenotype of CRF01_AE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-4808-3","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T14:02:52Z","timestamp":1582725772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China"],"prefix":"10.1186","volume":"20","author":[{"given":"Zesong","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"key":"4808_CR1","unstructured":"HIV\/AIDS-Key facts. World Health Organization. 2018. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hiv-aids. Accessed 19 July 2018."},{"key":"4808_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","volume":"98","author":"L Men\u00e9ndez-Arias","year":"2013","unstructured":"Men\u00e9ndez-Arias L. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antivir Res. 2013;98:93\u2013120.","journal-title":"Antivir Res"},{"key":"4808_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","volume":"16","author":"The TenoRes Study Group","year":"2016","unstructured":"The TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis. 2016;16:565\u201375.","journal-title":"Lancet Infect Dis"},{"key":"4808_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","volume":"46","author":"DS Clutter","year":"2016","unstructured":"Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292\u2013307.","journal-title":"Infect Genet Evol"},{"key":"4808_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/cid\/civ963","volume":"62","author":"LM Hofstra","year":"2016","unstructured":"Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, et al. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin Infect Dis. 2016;62:655\u201363.","journal-title":"Clin Infect Dis"},{"key":"4808_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","volume":"18","author":"RK Gupta","year":"2018","unstructured":"Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18:346\u201355.","journal-title":"Lancet Infect Dis"},{"key":"4808_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1473-3099(18)30647-9","volume":"19","author":"J Hemelaar","year":"2019","unstructured":"Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Fleminger I, Kirtley S, et al. Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. Lancet Infect Dis. 2019;19:143\u201355.","journal-title":"Lancet Infect Dis"},{"key":"4808_CR8","doi-asserted-by":"publisher","first-page":"8979","DOI":"10.1128\/JVI.79.14.8979-8990.2005","volume":"79","author":"KK Ari\u00ebn","year":"2005","unstructured":"Ari\u00ebn KK, Abraha A, Qui\u00f1ones-Mateu ME, Kestens L, Vanham G, Arts EJ. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol. 2005;79:8979\u201390.","journal-title":"J Virol"},{"key":"4808_CR9","doi-asserted-by":"publisher","first-page":"e1000365","DOI":"10.1371\/journal.ppat.1000365","volume":"5","author":"RM Troyer","year":"2009","unstructured":"Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, et al. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog. 2009;5:e1000365.","journal-title":"PLoS Pathog"},{"key":"4808_CR10","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","volume":"271","author":"AS Perelson","year":"1996","unstructured":"Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582\u20136.","journal-title":"Science."},{"key":"4808_CR11","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/jobm.201300415","volume":"54","author":"J Yang","year":"2014","unstructured":"Yang J, Geng W, Zhang M, Han X, Shang H. Discordance between genotypic resistance and pseudovirus phenotypic resistance in AIDS patients after long-term antiretroviral therapy and virological failure. J Basic Microbiol. 2014;54:1120\u20135.","journal-title":"J Basic Microbiol"},{"key":"4808_CR12","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1128\/AAC.04215-14","volume":"59","author":"AE Basson","year":"2015","unstructured":"Basson AE, Rhee SY, Parry CM, El-Khatib Z, Charalambous S, De Oliveira T, et al. Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2015;59:960\u201371.","journal-title":"Antimicrob Agents Chemother"},{"key":"4808_CR13","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1093\/jac\/dkt146","volume":"68","author":"L Anta","year":"2013","unstructured":"Anta L, Blanco JL, Llibre JM, Garc\u00eda F, P\u00e9rez-El\u00edas MJ, Aguilera A, et al. Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. J Antimicrob Chemother. 2013;68:1994\u20132002.","journal-title":"J Antimicrob Chemother"},{"key":"4808_CR14","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1128\/JVI.70.10.7013-7029.1996","volume":"70","author":"F Gao","year":"1996","unstructured":"Gao F, Robertson DL, Morrison SG, Hui H, Craig S, Decker J, et al. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (a\/E) recombinant of African origin. J Virol. 1996;70:7013\u201329.","journal-title":"J Virol"},{"key":"4808_CR15","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1089\/aid.2016.0029","volume":"32","author":"X Li","year":"2016","unstructured":"Li X, Li W, Zhong P, Fang K, Zhu K, Musa TH, et al. Nationwide trends in molecular epidemiology of HIV-1 in China. AIDS Res Hum Retrovir. 2016;32:851\u20139.","journal-title":"AIDS Res Hum Retrovir"},{"key":"4808_CR16","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1038\/s41598-017-06573-6","volume":"7","author":"X Wang","year":"2017","unstructured":"Wang X, He X, Zhong P, Liu Y, Gui T, Jia D, et al. Phylodynamics of major CRF01_AE epidemic clusters circulating in mainland of China. Sci Rep. 2017;7:6330.","journal-title":"Sci Rep"},{"key":"4808_CR17","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/QAD.0b013e328360db2d","volume":"27","author":"Y Feng","year":"2013","unstructured":"Feng Y, He X, Hsi JH, Li F, Li X, Wang Q, et al. The rapidly expanding CRF01_AE epidemic in China is driven by multiple lineages of HIV-1 viruses introduced in the 1990s. AIDS. 2013;27:1793\u2013802.","journal-title":"AIDS"},{"key":"4808_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12985-018-1112-6","volume":"16","author":"J Li","year":"2019","unstructured":"Li J, Xu Y, Liu J, Yang B, Yang C, Zhang M, et al. Drug resistance evolution in patients with human immunodeficiency virus-1 under long-term antiretroviral treatment-failure in Yunnan Province. China Virol J. 2019;16:5.","journal-title":"China Virol J"},{"key":"4808_CR19","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1093\/jac\/dkz134","volume":"74","author":"GA Yendewa","year":"2019","unstructured":"Yendewa GA, Sahr F, Lakoh S, Ruiz M, Pati\u00f1o L, Tabernilla A, et al. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone. J Antimicrob Chemother. 2019;74:2024\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"4808_CR20","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1186\/s12879-014-0689-7","volume":"14","author":"Y Jiao","year":"2014","unstructured":"Jiao Y, Li S, Li Z, Zhang Z, Zhao J, Li L, et al. HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-na\u00efve MSM from 2011 to 2013 in Beijing. China BMC Infect Dis. 2014;14:689.","journal-title":"China BMC Infect Dis"},{"key":"4808_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12981-019-0218-2","volume":"16","author":"AFY Poon","year":"2019","unstructured":"Poon AFY, Ndashimye E, Avino M, Gibson R, Kityo C, Kyeyune F, et al. First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda. AIDS Res Ther. 2019;16:3.","journal-title":"AIDS Res Ther"},{"key":"4808_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.antiviral.2010.04.001","volume":"87","author":"S Saeng-aroon","year":"2010","unstructured":"Saeng-aroon S, Tsuchiya N, Auwanit W, Ayuthaya PI, Pathipvanich P, Sawanpanyalert P, et al. Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: follow-up study from the Lampang cohort. Antivir Res. 2010;87:22\u20139.","journal-title":"Antivir Res"},{"key":"4808_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ebiom.2017.03.024","volume":"18","author":"SY Rhee","year":"2017","unstructured":"Rhee SY, Varghese V, Holmes SP, Van Zyl GU, Steegen K, Boyd MA, et al. Mutational correlates of Virological failure in individuals receiving a WHO-recommended Tenofovir-containing first-line regimen: An international collaboration. EBioMedicine. 2017;18:225\u201335.","journal-title":"EBioMedicine"},{"key":"4808_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/QAI.0000000000000467","volume":"68","author":"B Zhao","year":"2015","unstructured":"Zhao B, Han X, Xu J, Hu Q, Chu Z, Zhang J, et al. Increase of RT-related transmitted drug resistance in non-CRF01_AE among HIV type 1-infected men who have sex with men in the 7 cities of China. J Acquir Immune Defic Syndr. 2015;68:250\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4808_CR25","unstructured":"World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach; 2013."},{"key":"4808_CR26","doi-asserted-by":"publisher","first-page":"34729","DOI":"10.1038\/srep34729","volume":"6","author":"X Li","year":"2016","unstructured":"Li X, Xue Y, Lin Y, Gai J, Zhang L, Cheng H, et al. Evolutionary dynamics and complicated genetic transmission network patterns of HIV-1 CRF01_AE among MSM in Shanghai. China Sci Rep. 2016;6:34729.","journal-title":"China Sci Rep"},{"key":"4808_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/QAI.0b013e3182932210","volume":"64","author":"X Han","year":"2013","unstructured":"Han X, An M, Zhang M, Zhao B, Wu H, Liang S, et al. Identification of 3 distinct HIV-1 founding strains responsible for expanding epidemic among men who have sex with men in 9 Chinese cities. J Acquir Immune Defic Syndr. 2013;64:16\u201324.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4808_CR28","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/bioinformatics\/btu154","volume":"30","author":"Z Li","year":"2014","unstructured":"Li Z, Huang Y, Ouyang Y, Jiao Y, Xing H, Liao L, et al. CorMut: an R\/bioconductor package for computing correlated mutations based on selection pressure. Bioinformatics. 2014;30:2073\u20135.","journal-title":"Bioinformatics"},{"key":"4808_CR29","doi-asserted-by":"publisher","first-page":"e0170139","DOI":"10.1371\/journal.pone.0170139","volume":"12","author":"P Liu","year":"2017","unstructured":"Liu P, Feng Y, Wu J, Tian S, Su B, Wang Z, et al. Polymorphisms and mutational Covariation associated with death in a prospective cohort of HIV\/AIDS patients receiving long-term ART in China. PLoS One. 2017;12:e0170139.","journal-title":"PLoS One"},{"key":"4808_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","volume":"13","author":"BJ Callahan","year":"2016","unstructured":"Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13:581\u20133.","journal-title":"Nat Methods"},{"key":"4808_CR31","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1371\/journal.pmed.0020112","volume":"2","author":"R Kantor","year":"2005","unstructured":"Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2:e112.","journal-title":"PLoS Med"},{"key":"4808_CR32","doi-asserted-by":"publisher","first-page":"12402","DOI":"10.1128\/JVI.00262-12","volume":"86","author":"M An","year":"2012","unstructured":"An M, Han X, Xu J, Chu Z, Jia M, Wu H, et al. Reconstituting the epidemic history of HIV strain CRF01_AE among men who have sex with men (MSM) in Liaoning, northeastern China: implications for the expanding epidemic among MSM in China. J Virol. 2012;86:12402\u20136.","journal-title":"J Virol"},{"key":"4808_CR33","first-page":"720","volume":"30","author":"CL Cheng","year":"2009","unstructured":"Cheng CL, Feng Y, He X, Lin P, Liang SJ, Yi ZQ, et al. Genetic characteristics of HIV-1 CRF01_AE strains in four provinces, southern China. Zhonghua Liu Xing Bing Xue Za Zhi. 2009;30:720\u20135.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"4808_CR34","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.3390\/v6103855","volume":"6","author":"A Langs-Barlow","year":"2014","unstructured":"Langs-Barlow A, Paintsil E. Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomes. Viruses. 2014;6:3855\u201372.","journal-title":"Viruses"},{"key":"4808_CR35","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1097\/QAD.0b013e3283636179","volume":"27","author":"NE Mackie","year":"2013","unstructured":"Mackie NE, Dunn DT, Dolling D, Garvey L, Harrison L, Fearnhill E, et al. The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS. 2013;27:2245\u201353.","journal-title":"AIDS"},{"key":"4808_CR36","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/jmv.21567","volume":"81","author":"D Turner","year":"2009","unstructured":"Turner D, Shahar E, Katchman E, Kedem E, Matus N, Katzir M, et al. Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel. J Med Virol. 2009;81:1509\u201312.","journal-title":"J Med Virol"},{"key":"4808_CR37","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1097\/QAD.0b013e328356886d","volume":"26","author":"H Sunpath","year":"2012","unstructured":"Sunpath H, Wu B, Gordon M, Hampton J, Johnson B, Moosa MY, et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. AIDS. 2012;26:1679\u201384.","journal-title":"AIDS"},{"key":"4808_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1742-4690-6-101","volume":"6","author":"W Shao","year":"2009","unstructured":"Shao W, Kearney M, Maldarelli F, Mellors JW, Stephens RM, Lifson JD, et al. RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy. Retrovirology. 2009;6:101.","journal-title":"Retrovirology"},{"key":"4808_CR39","doi-asserted-by":"publisher","first-page":"e93804","DOI":"10.1371\/journal.pone.0093804","volume":"9","author":"Y Huang","year":"2014","unstructured":"Huang Y, Li Z, Xing H, Jiao Y, Ouyang Y, Liao L, et al. Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strains. PLoS One. 2014;9:e93804.","journal-title":"PLoS One"},{"key":"4808_CR40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.antiviral.2009.04.001","volume":"83","author":"L Monno","year":"2009","unstructured":"Monno L, Scudeller L, Brindicci G, Saracino A, Punzi G, Chirianni A, et al. Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from na\u00efve and treated subjects. Antivir Res. 2009;83:118\u201326.","journal-title":"Antivir Res"},{"key":"4808_CR41","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/jmv.24320","volume":"88","author":"A Jiamsakul","year":"2016","unstructured":"Jiamsakul A, Chaiwarith R, Durier N, Sirivichayakul S, Kiertiburanakul S, Van Den Eede P, et al. Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01_AE and subtype B HIV-infected individuals. J Med Virol. 2016;88:234\u201343.","journal-title":"J Med Virol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4808-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-4808-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4808-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T19:12:45Z","timestamp":1614193965000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-4808-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4808"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-4808-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.14340\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.14340\/v2","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,26]]},"assertion":[{"value":"6 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the First Affiliated Hospital of China Medical University and all subjects provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no competing interests associated with this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}